1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses

2: Managing EGFR inhibitor side effects in NSCLC - Skin toxicity impact, adherence challenges, and nursing management

ASCO 2026: Highlights and analysis

ASCO 2026: Latest in prostate cancer

Structured exercise programme improves survival and reduces healthcare costs in colon cancer

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups

Weight loss intervention improves quality of life in breast cancer survivors

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

Mobile app-based symptom monitoring helps maintain quality of life in advanced cancer

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer